It is unfortunate that the data cutoff date was 10 March, so we are missing a month, but even so the BORR for the KEYNOTE study seems to be 13/41 or 32% and Disease control of 24/41 58%.
It appears at mo that CAVATAK may more suited to the Yervoy trial than Keytruda, though they are different types of trial.
Latest clinical trial results, page-8
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)